

## Anti-COVID-19 & SARS-CoV S glycoprotein [CR3022] Isoblend 100 ug Ab01680-46.0-ISS

This is an antibody blend consisting of equal amounts (by mass) of IgG1, IgG3, IgM and IgA. The total antibody concentration is 1 mg/ml, which each format being present at 0.25 mg/ml.

This is a blend of IgG1, IgG3, IgM and IgA versions of CR3022. Each antibody format is present at 0.25 mg/ml, for a total antibody concentration of 1 mg/ml.

**Isotype and Format:** Human IgG1/IgG3/IgM/IgA, Isoblend, Kappa

**Clone Number:** CR3022

**Alternative Name(s) of Target:** Spike protein; COVID19; COVID 19; S protein; SARS-CoV S protein; S glycoprotein; E2; Peplomer protein; Spike protein S1; SARS Coronavirus; SARS-CoV-2; SARS CoV 2; 2019-nCoV; Ab1680.10; Ab1680.15; Ab1680.16

**UniProt Accession Number of Target Protein:** P59594

**Published Application(s):** crystallography, NTRL, SPR, ELISA, IF

**Published Species Reactivity:** SARS-CoV-2 (COVID-19) & SARS Coronavirus

**Immunogen:** The original monoclonal antibody was generated through an scFv library derived from a peripheral blood lymphocytes of a patient exposed to the SARS-CoV.

**Specificity:** This antibody binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020).

**Application Notes:** This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-competing SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has

been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020). Bates et al. 2021 (PMID: 32766589) used CR3022 in a immunofluorescence assay.

**Antibody First Published in:** ter Meulen et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants PLoS Med. 2006 Jul; 3(7): e237 [PMID:16796401](#)

**Note on publication:** Describes the discovery and original characterization of this antibody.

## Product Form

**Size:** 100 µg Isoblend products are precisely defined blends of IgG1, IgG3, IgM and IgA isotypes/subtypes. Each antibody format is present at 0.25 mg/ml, for a total antibody concentration of 1 mg/ml.

**Purification:** IgG1/IgG3 by protein A, IgM/IgA by recombinant lectin column

**Supplied In:** PBS with 0.02% Proclin 300

**Storage Recommendation:** Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.